Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis

Alexander Egeberg, Lars Erik Bryld, Lone Skov

48 Citations (Scopus)

Abstract

BACKGROUND: Biologics targeting interleukin 17 are increasingly being used for treatment of moderate-to-severe psoriasis, but data on drug survival for these therapies remain scarce.

OBJECTIVES: To investigate the drug survival of secukinumab and ixekizumab in a nationwide cohort of patients with psoriasis in Denmark.

METHODS: Using DERMBIO, we examined Danish patients receiving treatment with secukinumab or ixekizumab according to the standard in-label dosing. Kaplan-Meier plots were used to present survival curves.

RESULTS: In all, 368 and 62 patients received treatment with secukinumab and ixekizumab, respectively. In total, 40.7% and 12.9% of secukinumab- and ixekizumab-treated patients were bionaive. Ixekizumab-treated patients had received significantly more previous treatments. Over 12 months, 23.5% and 0.0% of bionaive secukinumab- and ixekizumab-treated patients discontinued therapy, respectively. Drug survival for bionaive and non-naive patients was lower for secukinumab than for ixekizumab. During the maximum 3 years of follow-up, secukinumab drug survival was lowest for patients who had previously been treated with 2 or more biologics, followed by patients treated with secukinumab as their second-ever biologic.

LIMITATIONS: The total number of patients and follow-up time were modest.

CONCLUSIONS: Drug survival was higher for ixekizumab even though secukinumab-treated patients had been treated with significantly fewer biologics before starting this drug.

Original languageEnglish
JournalJournal of the American Academy of Dermatology
Volume81
Issue number1
Pages (from-to)173-178
Number of pages6
ISSN0190-9622
DOIs
Publication statusPublished - Jul 2019

Keywords

  • biologics
  • drug survival
  • IL-17
  • ixekizumab
  • psoriasis
  • secukinumab

Fingerprint

Dive into the research topics of 'Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis'. Together they form a unique fingerprint.

Cite this